BCa isn't my best area, but a couple of observations...
600mg bid is a LOT of drug. It will be interesting to see how this performs in broader patient populations.
They have a future trial design problem trying to figure out how to deal with T-DM1 in terms of choosing a path to approval. What have they guided for their next trial indication and design?
Market Data 
Markets 
AI
